Onkologie. 2015:9(2):93-95

Position of sublingual fentanyl (Lunaldin®) in oncological clinical practice

Luboš Holubec1,2, Ondřej Fiala1,2, Vít Martin Matějka1, Jindřich Fínek1
1 Onkologická a radioterapeutická klinika FN a LF UK Plzeň
2 Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze

The present article accompanied by a clinical case report highlights the pitfalls frequently encountered in the common practice of a clinical

oncologist. In the introduction, the management of tumour pain is characterized with a focus on errors that can occur in everyday

practice. Next, the algorithm of diagnosing and treating breakthrough pain is analyzed in detail. The present case report emphasizes the

importance of a good-quality combination therapy for chronic and breakthrough pain that can substantially contribute to improving

the quality of life of a patient with multiple generalized tumour disease.

Keywords: pain treatment algorithm, chronic pain, breakthrough pain, quality of life

Published: April 10, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holubec L, Fiala O, Matějka VM, Fínek J. Position of sublingual fentanyl (Lunaldin®) in oncological clinical practice. Onkologie. 2015;9(2):93-95.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hakl M, a kol. Léčba bolesti - současné přístupy k léčbě bolesti a bolestivých syndromů. Praha. Mladá fronta, 2013: 214-225.
    2. Ela S, Espinosa J, Martínez-Mu?oz M, Lasmarías C, et al. The WHO collaborating centre for public health palliative care programs: an innovative approach of palliative care development. J Palliat Med, 2014; 17 (4): 385-392. Go to original source... Go to PubMed...
    3. Haugen DF, Hjermstad MJ, Hagen N, et al. European Palliative Care Research Collaborative (EPCRC). Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain, 2010; 49 (3): 476-482. Go to original source... Go to PubMed...
    4. Neudertová H. In: Hakl M, a kol. Léčba bolesti - současné přístupy k léčbě bolesti a bolestivých syndromů. Praha. Mladá fronta, 2013: 37-48.
    5. Hegmonová E. Léčba chronické bolesti silnými opioidy. Interní Med, 2014; 16 (3): 102-106.
    6. Sysáková A. Zásady medikamentóznej liečby chronickej bolesti v geriatrii. Geriatria, 2013; 2: 68-75.
    7. Holubec L, Mrázková P, Matějka VM, et al. Léčba polyneuropatické bolesti u nemocného s generalizovaným, kastračně rezistentním karcinomem prostaty - klinická kazuistika. Klin Onkol, 2013; 26 (5): 354-357. Go to original source... Go to PubMed...
    8. Lejčko J. Možnosti léčby nádorové bolesti. Acta Medicinae, 2013; 8: 68-72.
    9. Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, Gebbia V. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain, 2010; 26 (9): 794-797. Go to original source... Go to PubMed...
    10. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage, 2002; 24 (1): 45-52. Go to original source... Go to PubMed...
    11. Nosková P. Průlomová bolest a její léčba. Interní Med, 2010; 12 (10): 482-486.
    12. Hakl M, Ševčík P. Opioidní analgetika v léčbě chronické bolesti. Remedia, 2012 22 (6): 408-411.
    13. Slater H, Briggs AM, Smith AJ, et al. Implementing evidence-informed policy into practice for health care professionals managing people with low back pain in Australian rural settings: a preliminary prospective single-cohort study. Pain Med, 2014; 15 (10): 1657-1668. Go to original source... Go to PubMed...
    14. Kršiak M. Novinky ve farmakologii opioidů s významem pro praxi. Paliat.med. liečba bolesti, 2010; 3 (1): 28-30.
    15. Fricová J. Současné možnosti léčby průlomové bolesti u onkologických pacientů. Remedia, 2011; 21:14-19.
    16. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage, 2013; 46 (4): 573-580. Go to original source... Go to PubMed...
    17. Überall MA, Müller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin, 2011; 27 (7): 1385-1394. Go to original source... Go to PubMed...
    18. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin, 2009; 25: 2877-2885. Go to original source... Go to PubMed...
    19. Lennernäs B, Frank-Lissbrant I, Lennernäs H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliative Medicine, 2010; 24: 286-293. Go to original source... Go to PubMed...
    20. Moore N, Darwish M, Amores X, Schneid H. A review of the pharmacokinetic profile of transmucosal fentanyl formulations. Curr Med Res Opin, 2012; 28 (11): 1781-1790. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.